Live
Activity: 12/04/2024
Activity
Launch Date: 06/24/2024
Activity
Expiration Date: 06/24/2027
Overview
The lack of standardization in clinical decision
making among health care providers can lead to inconsistent patient outcomes,
higher costs, and lower quality of care. Clinical practice guidelines (CPGs)
provide evidence-based recommendations for providers, which in turn promotes
efficient care. CPGs can affect all aspects of epilepsy treatment, from how
physicians make decisions to how insurance companies make reimbursements.
However, development and implementation of CPGs can be challenging, and there
is a need for ongoing evaluation and refinement of CPGs to ensure their
effectiveness. Currently, AES is leading two CPGs in development, and
co-developing additional CPGs with other societies, as well as endorsing
guidelines from other societies on a regular basis. AES and other organizations
have procedures for developing CPGs that are similar, but not identical.
Moreover, different countries have different methods for developing and using
CPGs. Many AES members are unfamiliar with the methods by which CPGs are
developed, and how the AES process is different from that of other societies
and other countries. In addition, many members are unsure how to incorporate
guidelines into clinical practice.
This symposium introduces attendees to CPG,
including guideline development, comparisons of guideline development
processes, incorporating guidelines into clinical practice, and the limitations
of guidelines particularly when randomized controlled trials are not available.
Learning Objectives
Following participation in this activity,
participants will be able to:
- Appraise how guidelines are developed
- Describe CPG development methodology
- Implement CPGs in clinical practice
Chairs
Aatif Husain, MD,
and Emily Johnson, MD, FAES
Program
Introduction | Aatif Husain, MD
Why are Guidelines Important? | Renad Abu-Sawwa,
PharmD
What is a Guideline (Overview of Development)? |
Aatif Husain, MD
US vs. International Guidelines: Similarities
and Differences | Paul Cooper, DM, MA, FRCP, FAES
How to Incorporate Guidelines into Clinical
Practice | Karen Skjei, MD, FAES
What are the Limitations of Clinical Practice
Guidelines? | Emily Johnson, MD, FAES
Panel Discussion | All Faculty
Target Audience
Advanced Practice Providers (APPs), Advocates,
Behavioral Health Providers, Clinicians, Community Health Workers,
Fellows/Trainees, Nurses, Pharmacists, Scientists/Researchers, Social Workers,
Technicians
FACULTY/PLANNER DISCLOSURES
It is the policy of the AES to make disclosures of
financial relationships of faculty, planners and staff involved in the
development of educational content transparent to learners. All faculty
participating in continuing medical education activities are expected to
disclose to the program audience (1) any real or apparent conflict(s) of
interest related to the content of their presentation and (2) discussions of
unlabeled or unapproved uses of drugs or medical devices. AES carefully reviews
reported conflicts of interest (COI) and resolves those conflicts by having an
independent reviewer from the CME Review Committee validate the content of all
presentations for fair balance, scientific objectivity, and the absence of
commercial bias. The American Epilepsy Society adheres to the ACCME’s Essential
Areas and Elements regarding industry support of continuing medical education;
disclosure by faculty of commercial relationships, if any, and discussions of
unlabeled or unapproved uses will be made.
Planning
Committee, Faculty, Reviewers’ Disclosures of Financial Relationships
In accordance with the ACCME Standards for
Integrity and Independence in Accredited Continuing Education, the AES requires
that any person who is in a position to control content of a CME activity must
disclose all relevant financial relationships that they have with an ineligible
company. Unless otherwise indicated (*), none of the planners or faculty of
this activity have any financial relationships to disclose. All relevant
financial relationships with ineligible companies have been mitigated. The following
individuals contributed to this activity’s content.
CME Reviewer
Dawn Eliashiv, MD,
FAAN, FAES
Resolution of Conflicts of Interest
It is the policy of the American Epilepsy Society
to ensure balance, independence, objectivity and scientific rigor. All persons
involved in the selection, development and presentation of content are required
to disclose any real or apparent conflicts of interest. In accordance with the
ACCME Standards of Integrity and Independence in Accredited Continuing
Education, the AES implemented the mechanisms of prospective peer review of
this CME activity, to identify and resolve any conflicts. Additionally, the content
of this activity is based on the best available evidence.
Accreditation
The American Epilepsy Society is accredited by the
Accreditation Council for Continuing Medical Education to provide continuing
medical education for physicians.
For more information regarding contact hours,
please call American Epilepsy Society 312.883.3800.
Credit
Designation
The American Epilepsy Society designates this live
activity for a maximum of 2.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with
the extent of their participation in the activity.
CME and CE Certificates
To receive credit for your participation in this
activity, please complete the evaluation survey provided at the conclusion of
the activity.
Unapproved
Use Disclosure
The American Epilepsy Society requires CME authors
to disclose to learners when products or procedures being discussed are
off-label, unlabeled, experimental, and/or investigational (not FDA approved);
and any limitations on the information that is presented, such as data that are
preliminary or that represent ongoing research, interim analyses, and/or
unsupported opinion. This information is intended solely for continuing medical
education and is not intended to promote off-label use of these medications. If
you have questions, contact the medical affairs department of the manufacturer
for the most recent prescribing information. Information about pharmaceutical
agents/devices that is outside of U.S. Food and Drug Administration approved
labeling may be contained in this activity.
Disclaimer
This CME activity is for educational purposes only
and does not constitute the opinion or endorsement of, or promotion by, the
American Epilepsy Society. Reasonable efforts have been taken to present
educational subject matter in a balanced, unbiased fashion, and in compliance
with regulatory requirements. However, each activity participant must always
use his or her own personal and professional judgment when considering further
application of this information, particularly as it may relate to patient diagnostic
or treatment decisions including, without limitation, FDA-approved uses and any
off-label, investigational and/or experimental uses.